{"id":39572,"date":"2026-09-08T10:12:00","date_gmt":"2026-09-08T14:12:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39572"},"modified":"2026-08-31T22:48:10","modified_gmt":"2026-09-01T02:48:10","slug":"stop-assuming-spc-terms-mirror-us-patent-term-extension-the-math-differs-by-country","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/stop-assuming-spc-terms-mirror-us-patent-term-extension-the-math-differs-by-country\/","title":{"rendered":"Stop Assuming SPC Terms Mirror US Patent Term Extension: The Math Differs by Country"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

A Supplementary Protection Certificate in Germany and a Patent Term Extension in the United States both advertise the same headline number: up to five years. Beyond that, the resemblance mostly ends. The United States discounts half of a drug’s clinical testing phase before it counts a single day toward the extension. The European Union does not discount anything \u2014 it takes the raw number of days between patent filing and first marketing authorization and subtracts exactly five years. Japan starts its clock on a different date entirely, depending on whether a patent was granted before or after a company began human trials. South Korea only counts time spent inside Korea, no matter how long the drug sat in an American or European regulatory queue first. Canada caps the whole exercise at two years, not five, under a formula inherited from a trade agreement rather than a domestic Hatch-Waxman-style bargain.<\/p>\n\n\n\n

None of this is exotic trivia. It is the daily operating reality for any company tracking loss-of-exclusivity dates across more than one jurisdiction, and it is also the point where in-house teams most often make an avoidable modeling error: assuming that because a jurisdiction says “five years maximum,” its math behaves like the jurisdiction they already understand. It does not. This article works through the actual calculation mechanics \u2014 statute by statute, formula by formula \u2014 across the seven jurisdictions that matter most for global pharmaceutical patent strategy, using real cases and real regulatory records rather than the rounded generalizations that circulate in most comparative summaries. Patent intelligence platforms such as DrugPatentWatch exist precisely because a spreadsheet with a single “extended expiration date” column cannot capture this much divergence.<\/p>\n\n\n\n

The Short Answer<\/strong><\/h2>\n\n\n\n

The United States, European Union\/United Kingdom, Japan, China, South Korea, Australia, and Canada all offer some form of pharmaceutical patent term extension, and five of the seven cap the extension at five years. But the formulas that get a patent holder to that number are not interchangeable. The US formula discounts clinical-trial time by half; the EU, UK, China, and Australian formulas do not discount anything \u2014 they subtract a flat five years from the full filing-to-approval interval. Japan runs a “later of two start dates, day before notification” calculation that is not a subtraction at all in the EU sense. South Korea only counts domestic regulatory time and applies an all-or-nothing rule that has no real analogue elsewhere. Canada’s Certificate of Supplementary Protection caps out at two years regardless of how long the regulatory delay actually was. A peer-reviewed comparative study of the same drug set found that European SPC terms ran, on average, 1.55 years longer than US PTE terms for identical products, even though both nominally cap at five years [23]<\/a>.<\/p>\n\n\n\n

Why “Five Years Maximum” Doesn’t Mean “Five Years Comparable”<\/strong><\/h2>\n\n\n\n

The five-year ceiling is a coincidence of drafting, not evidence of a shared calculation method. The United States adopted its ceiling in the 1984 Hatch-Waxman Act. The European Community adopted its own ceiling independently in 1992 under Regulation No. 1768\/92, later codified as Regulation (EC) No. 469\/2009 [4]<\/a>. Japan, China, South Korea, and Australia each legislated their own five-year caps on their own timelines, in some cases explicitly modeling the EU’s SPC concept and in other cases modeling the US PTE concept, and in at least one case (China) borrowing the EU’s arithmetic while borrowing the US’s total-term ceiling. Canada took neither approach and capped its mechanism at two years under a 2017 implementation of the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) [21]<\/a>.<\/p>\n\n\n\n

The practical consequence is that a portfolio manager who has internalized “our EU SPC math” cannot simply relabel the inputs and get a correct US, Japanese, Korean, or Canadian output. Each formula has its own start date, its own discount rules, its own scope of protected uses, and its own filing deadline. Getting any one of those wrong on a real filing is not a rounding error; it can cost a company months or years of exclusivity on a single product, in a single country, with no equitable remedy once the statutory window closes.<\/p>\n\n\n\n

How the US Calculates Patent Term Extension Under 35 U.S.C. \u00a7 156<\/strong><\/h2>\n\n\n\n

US Patent Term Extension traces to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly called the Hatch-Waxman Act, codified in relevant part at 35 U.S.C. \u00a7 156 [2]<\/a>. The statute does not simply hand back the entire regulatory review period. It applies a specific, non-intuitive formula that the US Patent and Trademark Office spells out in Chapter 2758 of the Manual of Patent Examining Procedure:<\/p>\n\n\n\n

PTE = \u00bd(TP \u2212 PGTP) + (RRP \u2212 PGRRP \u2212 DD)<\/strong><\/p>\n\n\n\n

Here, RRP is the total regulatory review period; PGRRP is the portion of that period that occurred on or before the date the patent issued; DD is any period during which the applicant failed to act with due diligence; TP is the testing-phase period, generally running from the date an Investigational New Drug application takes effect to the date the marketing application is submitted; and PGTP is the portion of that testing phase that occurred on or before the patent’s issue date [1]<\/a> [3]<\/a>.<\/p>\n\n\n\n

The Half-Testing-Phase Discount Nobody Outside the US Uses<\/strong><\/h3>\n\n\n\n

The operative detail is the one-half multiplier applied to the testing phase. Congress built this discount into the statute on the theory that a company retains some ability to exploit a pending patent during clinical development, even before marketing approval, so only half of that period should count toward the extension. No other major jurisdiction in this comparison applies an equivalent discount to its own testing or clinical-trial period. The EU, UK, China, and Australian formulas count the full elapsed period between filing and approval, discounted only by the flat five-year subtraction described below. This single structural difference is often the single largest reason a US PTE and an EU SPC for the same drug, calculated from broadly similar regulatory timelines, land on different extension lengths.<\/p>\n\n\n\n

The 60-Day Filing Window and the One-Patent-Per-Product Rule<\/strong><\/h3>\n\n\n\n

A PTE application must be submitted within 60 days of the product receiving permission for commercial marketing, and only one patent may be extended per approved product, regardless of how many patents cover different aspects of it [6]<\/a>. This is stricter on the multiple-patent question than South Korea, discussed below, where more than one patent covering the same approved product can separately qualify for extension.<\/p>\n\n\n\n

The 14-Year Ceiling Measured From Approval, Not From Filing<\/strong><\/h3>\n\n\n\n

Even where the formula above produces a large number, 35 U.S.C. \u00a7 156(c)(3) caps the extended term so that the remaining patent life plus the extension cannot exceed fourteen years measured from the date of product approval [8]<\/a>. This cap is measured from approval, not from the original filing date, which matters because it means a very early-filed patent with a long clinical delay can still be trimmed back to the fourteen-year ceiling even if the raw formula would have produced more.<\/p>\n\n\n\n

How the EU Calculates a Supplementary Protection Certificate Under Regulation 469\/2009<\/strong><\/h2>\n\n\n\n

The EU’s Supplementary Protection Certificate is not, legally, an extension of the original patent at all. It is a separate sui generis intellectual property right that takes effect only after the underlying patent expires, granted on a country-by-country basis at each national patent office even though the underlying regulation is EU-wide [4]<\/a>. There is no centralized EU body that issues a single SPC covering the whole bloc; an originator must file separately in Germany, France, Italy, and every other member state where protection is wanted, and national offices can and do reach different outcomes on the same product.<\/p>\n\n\n\n

The Straight-Subtraction Formula: Filing Date to First EEA Authorization, Minus Five<\/strong><\/h3>\n\n\n\n

Article 13(1) of Regulation 469\/2009 sets the duration as the period that elapsed between the date the basic patent application was filed and the date of the first authorization to place the product on the market in the European Economic Area, reduced by five years [5]<\/a>. There is no testing-phase discount, no half-multiplier, and no distinction between time before and after the patent issued. If a company filed its patent in 2003 and obtained its first EEA marketing authorization in 2016, the raw calculation is thirteen years minus five, or eight years \u2014 automatically capped at the five-year statutory maximum. If the same interval were only seven years, the SPC would run for two years, uncapped, because it falls under the ceiling. This straightforward subtraction is structurally simpler than the US formula and, critically, does not reward or penalize a company for how much of its clinical development happened before versus after patent grant, the way the US’s PGTP\/PGRRP mechanics do.<\/p>\n\n\n\n

Why the Notification Date, Not the Decision Date, Controls: Seattle Genetics<\/strong><\/h3>\n\n\n\n

For years, national patent offices disagreed on which of two possible dates should serve as “the date of the first authorisation”: the date the European Commission’s marketing authorization decision was issued, or the later date on which that decision was formally notified to the applicant. The gap is often only a few days, but a few days of SPC term is worth real money on a blockbuster product. In Seattle Genetics (Case C-471\/14), the Court of Justice of the European Union resolved the split for the antibody-drug conjugate Adcetris (brentuximab vedotin), holding that the correct reference date is the date of notification to the recipient, not the date of the Commission’s decision [6]<\/a>. In the underlying dispute, the Austrian Patent Office had used the earlier decision date of 25 October 2012 and fixed the SPC’s expiry at 25 October 2027; Seattle Genetics argued for the notification date of 30 October 2012, five days later, which the CJEU ultimately endorsed. National offices across the EU subsequently recalculated pending and pipeline SPCs to reflect the notification date, lengthening term for holders who had not already hit the five-year cap.<\/p>\n\n\n\n

Zero and Negative SPCs: The Merck Sitagliptin Case<\/strong><\/h3>\n\n\n\n

Because the EU formula is a straight subtraction, it can produce a negative number when the filing-to-approval interval is shorter than five years. Merck’s SPC application for sitagliptin phosphate monohydrate, the active ingredient in Januvia, calculated to a period of four years, eight months, and sixteen days between patent filing and first marketing authorization \u2014 short of the five-year threshold, producing a negative duration of roughly three and a half months [7]<\/a>. National offices split on whether to grant an SPC with a negative or zero term at all. In Merck (Case C-125\/10), the CJEU held that an SPC can be granted with a zero or negative duration, which matters because only a granted SPC can subsequently receive the six-month paediatric extension described below \u2014 and adding six months to even a negative three-and-a-half-month base can turn the total positive [7]<\/a> [8]<\/a>. A company that assumes, as under US practice, that a negative calculation simply means “no extension available” will miss this route entirely.<\/p>\n\n\n\n

The Six-Month Paediatric Bonus and Its Odd Timing<\/strong><\/h3>\n\n\n\n

Regulation (EC) No. 1901\/2006 grants a further six months on top of an SPC’s calculated duration where the holder has completed an EMA-agreed Paediatric Investigation Plan, regardless of whether the resulting paediatric studies were clinically favorable [8]<\/a>. This extension applies even to an SPC that has already reached the full five-year statutory cap, effectively raising the practical ceiling to five and a half years \u2014 a nuance the bare “five-year maximum” headline obscures.<\/p>\n\n\n\n

The United Kingdom’s Retained SPC Law Is Starting to Diverge From the EU’s<\/strong><\/h2>\n\n\n\n

When the UK left the EU, it did not scrap the SPC system; it incorporated the existing EU regulations into UK domestic law as retained EU law, preserving the same eligibility conditions, the same duration formula, the same five-year cap, and the same paediatric extension. Pre-Brexit CJEU rulings such as Seattle Genetics remain binding on UK courts, but UK courts now have the authority to depart from that precedent where they consider it appropriate, and the UK Intellectual Property Office administers UK SPCs as a wholly separate national grant from EU member-state SPCs on the same product.<\/p>\n\n\n\n

Same Formula, Different Courts: The Dapagliflozin Split<\/strong><\/h3>\n\n\n\n

The clearest illustration is not a disagreement about the SPC formula itself, but about whether the underlying patent survives long enough for the formula to matter. AstraZeneca’s UK SPCs covering dapagliflozin (Forxiga), numbered SPC\/GB13\/021 and SPC\/GB14\/050, were calculated to run to 13 and 14 May 2028 based on European Patent (UK) No. 1,506,211, which itself expired on 14 May 2023 [22]<\/a>. Generic challengers Teva, Glenmark, and Viatris sought revocation of both the underlying patent and the SPCs. The UK High Court, and subsequently the Court of Appeal, held the patent invalid for lack of inventive step and insufficient disclosure, applying a stringent “plausibility” standard that the courts acknowledged diverges from the European Patent Office’s more permissive approach under its Enlarged Board of Appeal decision G 2\/21 [22]<\/a>. The UK Supreme Court subsequently declined to hear AstraZeneca’s appeal. The arithmetic behind the UK and EU dapagliflozin SPCs was never in dispute; what diverged was whether UK courts, now free to apply their own plausibility jurisprudence, would let the underlying patent stand at all. The lesson for portfolio planning is that identical SPC math across the UK and EU no longer guarantees identical outcomes, because the two systems’ courts can now reach different conclusions about patent validity even from the same specification.<\/p>\n\n\n\n

Japan’s Patent Term Extension Runs on a Different Clock Entirely<\/strong><\/h2>\n\n\n\n

Japan’s patent term extension, provided under Article 67 of the Patent Act, caps at five years like the US and EU systems, but the period it measures is defined differently enough that calling it “an SPC” or “a PTE” both understate the difference.<\/p>\n\n\n\n

Later-of-Two-Start-Dates: Why Japan’s Formula Isn’t a Subtraction at All<\/strong><\/h3>\n\n\n\n

The extendable period in Japan begins on whichever is later: the day a clinical trial begins, generally treated as the day an investigational new drug application takes effect, or the day the patent is registered. It ends on the day immediately before the day the regulatory approval notice is mailed to the applicant [10]<\/a>. Unlike the EU’s single subtraction of a flat five years from a filing-to-approval interval, the Japanese calculation is a direct count of “days the patent could not be worked” bounded by whichever of two starting events came later, with no separate five-year offset built into the arithmetic itself \u2014 the five-year figure in Japan is purely an external cap on the result, not an input to the formula the way it is in the EU calculation.<\/p>\n\n\n\n

What Counts as “Working” the Patent: The Bevacizumab Ruling<\/strong><\/h3>\n\n\n\n

Japan’s Supreme Court has twice had to define what “unable to work the patented invention” actually means in the extension context, because the answer determines how much of the calculated period actually counts. In the earlier Pacif case, the Court held that a patent term extension based on a later regulatory approval is not automatically denied merely because an earlier approval did not fall within the technical scope of the patented invention. In the subsequent Bevacizumab case \u2014 concerning Genentech\/Chugai’s Avastin \u2014 the Supreme Court went further and rejected the Japan Patent Office’s own examination guidelines, holding that where the product covered by an earlier disposition already fully includes the product covered by a later disposition on which the extension application relies, the later disposition was not, in fact, “necessary,” and an extension premised on it can be denied [11]<\/a>. The JPO revised its examination guidelines in 2016 to align with the ruling. The practical effect is that a company holding multiple regulatory approvals in Japan for overlapping formulations of the same active ingredient cannot assume that every later approval automatically supports a fresh extension request; the scope-overlap analysis the Supreme Court laid out determines that on a case-by-case basis.<\/p>\n\n\n\n

Multiple Approvals, Multiple Extensions: Japan’s Repeat-Filing Advantage<\/strong><\/h3>\n\n\n\n

Subject to the Bevacizumab scope test above, Japan is unusual among the jurisdictions compared here in that any category of regulatory approval \u2014 not only a product’s first approval \u2014 can in principle support a term-extension request, whereas most other systems tie eligibility strictly to the first approval of the active ingredient. Comparative data compiled by Japanese patent practitioners puts the average commercial “protection of product” period after approval at roughly six years in Japan, with an average extension of roughly four years, against an average post-approval protection period of roughly eleven years and an average extension of roughly three years in the United States [11]<\/a>. That inverse relationship \u2014 Japan grants a larger average extension precisely because its unextended post-approval runway tends to be shorter \u2014 is a useful reminder that comparing raw extension lengths across countries without also comparing the underlying development timelines can be misleading in either direction.<\/p>\n\n\n\n

China’s Patent Term Compensation Copies the EU’s Math, Not the US’s<\/strong><\/h2>\n\n\n\n

China’s patent term compensation mechanism for new drugs, introduced by the fourth amendment to the Patent Law effective 1 June 2021 and detailed in Implementing Regulations that took effect 20 January 2024, is administered by the China National Intellectual Property Administration (CNIPA) [12]<\/a>. Article 42, paragraph 3 of the Patent Law caps the compensation period at five years and caps the total effective patent term after marketing approval at fourteen years \u2014 explicitly borrowing the US’s 14-year post-approval ceiling \u2014 while the underlying formula borrows the EU’s straight-subtraction approach rather than the US’s half-testing-phase discount.<\/p>\n\n\n\n

CNIPA’s own published equations state the compensation term as the date of marketing approval in China minus the patent’s filing date minus five years, capped at five years, with the second-stage cap holding the total effective term (time remaining to the twenty-year mark plus any patent term adjustment plus the PTE compensation) to no more than fourteen years from marketing approval [13]<\/a>. Patentees must file within three months of marketing authorization.<\/p>\n\n\n\n

The Camrelizumab Case and What a Five-Year Ceiling Looks Like in Practice<\/strong><\/h3>\n\n\n\n

On 17 December 2024, CNIPA approved a patent term compensation request for composition patent ZL03156365.1 covering camrelizumab, an anti-PD-1 antibody with nine approved indications in China including refractory classical Hodgkin lymphoma, granting a compensation period of 1,827 days, or approximately five years \u2014 the full statutory maximum [12]<\/a>. Chinese IP commentary treats this as the longest compensation period granted to a biologic under the new system to date, illustrating that China’s version of the five-year cap behaves the same way the EU’s does: as a hard ceiling that a sufficiently long development-and-review timeline will simply hit.<\/p>\n\n\n\n

Early Cohort Data: How Often Chinese Drugs Actually Reach the Cap<\/strong><\/h3>\n\n\n\n

A peer-reviewed cohort study tracking 148 innovative drugs approved in China between June 2021 and December 2024 found that 61 percent obtained patent term extension, with a median extension duration of five years and an interquartile range of 2.3 to 5 years [14]<\/a>. The same study explicitly notes that China’s calculation model mirrors the EU’s simple subtraction approach rather than the US’s more complex testing-phase-discounted formula, while still importing the US-style 14-year effective-term ceiling \u2014 making China something of a hybrid between the two older systems rather than a clone of either.<\/p>\n\n\n\n

South Korea’s Formula Only Counts Time Spent Inside Korea<\/strong><\/h2>\n\n\n\n

South Korea’s Patent Act allows extensions of up to five years for pharmaceuticals and agrochemicals, administered by the Korean Intellectual Property Office (KIPO), but the underlying calculation departs from every other system discussed here in one important respect: it does not measure the full global filing-to-approval interval at all.<\/p>\n\n\n\n

The extendable period in Korea is calculated by adding the duration of domestic clinical trials conducted in Korea to the time taken for Korea’s own regulatory approval review, and then subtracting any delay attributable to the marketing-authorization holder [15]<\/a>. If a company ran its pivotal trials in the United States and Europe and only conducted a smaller bridging study in Korea before filing for Korean approval, only the Korean-based portion of that timeline feeds the extension calculation \u2014 a structurally different, and typically smaller, number than what the same underlying delay would produce under the EU’s full-interval subtraction or even the US’s discounted-but-still-global formula.<\/p>\n\n\n\n

The All-or-Nothing Rule That Makes Korean PTE Riskier to File<\/strong><\/h3>\n\n\n\n

KIPO applies what practitioners describe as an all-or-nothing rule: if KIPO rejects an applicant’s proposed calculation of the extension period, the result is no extension at all, rather than a reduced or corrected one [16]<\/a>. This is a meaningfully higher-stakes filing environment than the US or EU systems, where a disputed calculation typically results in a shorter, but nonzero, grant, subject to further administrative or judicial correction. Historical data cited in Korean IP commentary put the average extension length for Korean pharmaceutical patents at roughly 1.5 years \u2014 less than half the average extension length reported in the US, Europe, and Japan over the same period [16]<\/a>. A 2024-2025 revision to the Korean Patent Act introduced an additional 14-year total-term cap modeled on US practice, a change Korean IP commentary flags as likely to shorten some extensions further, particularly for drugs with long international development timelines relative to their Korean approval date [17]<\/a>.<\/p>\n\n\n\n

A Narrower Right: Why Korean Extensions Protect Less Than US or EU Ones<\/strong><\/h3>\n\n\n\n

Article 95 of the Korean Patent Act limits the scope of the extended right to the specific approved product and its specific approved uses, in contrast to the US and European systems, where the extended patent right generally covers any use of the approved active ingredient, including uses approved only after the extension was granted [16]<\/a>. Korea also permits more than one patent covering an approved product to separately qualify for extension, a departure from the US’s one-patent-per-product rule, though KIPO has signaled it may revisit that provision to align more closely with US and European practice [16]<\/a>.<\/p>\n\n\n\n

Australia’s “Earliest First Approval” Rule Can Punish You for Someone Else’s Filing<\/strong><\/h2>\n\n\n\n

Under sections 70, 71, and 77 of the Patents Act 1990 (Cth), an Australian pharmaceutical patent term extension runs for the period between the date of the patent and the earliest first regulatory approval date for any pharmaceutical substance disclosed and claimed in the patent, reduced by five years, capped at five years [19]<\/a> [20]<\/a>. That formula reads, on its face, much like the EU’s straight subtraction. The complication is in the word “earliest,” and in the definition of “first regulatory approval date” under section 70.<\/p>\n\n\n\n

The Pembrolizumab Dispute: Ono and Merck Sharp & Dohme v. Sandoz<\/strong><\/h3>\n\n\n\n

In two Federal Court of Australia appeal judgments handed down concurrently in March 2022 \u2014 Commissioner of Patents v. Ono Pharmaceutical Co. Ltd and Merck Sharp & Dohme Corp. v. Sandoz Pty Ltd \u2014 the Full Federal Court confirmed that the extension calculation under section 77 must use the earliest first regulatory approval date of any pharmaceutical substance disclosed and claimed in the relevant patent, regardless of whether the approved goods belong to the patentee itself or to a competing third party [18]<\/a>. The underlying MSD dispute concerned pembrolizumab, the active ingredient in Keytruda, where a broadly drafted patent claim covering a class of PD-1 antibodies meant that a third party’s earlier-approved antibody within that same claim scope could, under the Full Court’s reading, set the “earliest first regulatory approval date” that shortens the patentee’s own extension \u2014 rather than the date on which the patentee’s own product, pembrolizumab, was first approved [18]<\/a>. The Full Court explicitly rejected the argument that section 70(3) should be limited to “the patentee’s goods,” finding no textual basis in the statute for that narrower reading. The result is a jurisdiction-specific trap: a claim drafted broadly enough to capture more than one company’s product can shorten the patentee’s own available extension in Australia in a way that has no direct parallel in the US, EU, or Japanese formulas, all of which anchor the calculation to the patentee’s own first approval of the specific approved product.<\/p>\n\n\n\n

Canada’s Certificate of Supplementary Protection Caps Out at Two Years, Not Five<\/strong><\/h2>\n\n\n\n

Canada has no domestic Hatch-Waxman-style patent term restoration tradition of its own. Its Certificate of Supplementary Protection (CSP) was introduced as part of Canada’s 2017 implementation of the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), administered jointly by Health Canada and the Canadian Intellectual Property Office [21]<\/a>. A CSP compensates for time consumed by Health Canada’s regulatory review of a new medicinal ingredient, and the application must be filed within 120 days of receiving that regulatory approval.<\/p>\n\n\n\n

The maximum CSP term is two years \u2014 not five. This is the single sharpest numerical outlier among the jurisdictions compared in this article. A regulatory delay long enough to earn a company the full five-year cap in the US, EU, Japan, China, or Australia will, for the same drug, earn at most two years of supplementary protection in Canada, regardless of how much longer the underlying delay actually ran.<\/p>\n\n\n\n

Why CETA Produced a Shorter Cap Than Its EU Counterpart<\/strong><\/h3>\n\n\n\n

The two-year Canadian cap is notable precisely because CETA was negotiated with the EU, whose own SPC system caps at five years. Trade-negotiation compromises, not a shared policy judgment about how much regulatory delay pharmaceutical patents should be compensated for, produced the gap: Canada agreed to introduce a restoration mechanism as part of the broader CETA package, but implemented it at a substantially lower ceiling than its European counterpart. A company that has become accustomed to treating “the EU cap” and “the Canadian cap” as roughly equivalent because both trace back to the same trade agreement will overstate Canadian exclusivity by up to three years on any drug where the underlying regulatory delay was long enough to hit both ceilings.<\/p>\n\n\n\n

A Country-by-Country Comparison Table for Extension Mechanics<\/strong><\/h2>\n\n\n\n
Jurisdiction<\/th>Legal Basis<\/th>Core Formula<\/th>Max Extension<\/th>Total-Term Cap<\/th>Filing Deadline<\/th>Extended-Right Scope<\/th><\/tr><\/thead>
United States<\/td>35 U.S.C. \u00a7 156 (Hatch-Waxman, 1984)<\/td>\u00bd(testing phase, post-grant) + (review period, post-grant, minus applicant delay)<\/td>5 years<\/td>14 years from approval<\/td>60 days from approval<\/td>Approved active ingredient, broad use coverage; one patent per product<\/td><\/tr>
European Union<\/td>Regulation (EC) No. 469\/2009<\/td>Filing date to first EEA authorization, minus 5 years (straight subtraction)<\/td>5 years (5.5 with paediatric extension)<\/td>Structural 15-year target built into formula; no separate post-approval hard cap<\/td>6 months from MA or patent grant, whichever later<\/td>Approved product, broad use coverage; separate national grants per member state<\/td><\/tr>
United Kingdom<\/td>Retained EU Regulation 469\/2009 (post-Brexit domestic law)<\/td>Same as EU, but UK courts may depart from CJEU precedent<\/td>5 years (5.5 with paediatric extension)<\/td>Same structural target as EU<\/td>6 months from MA or patent grant, whichever later<\/td>Same as EU; independent grant and independent validity litigation from EU member states<\/td><\/tr>
Japan<\/td>Patent Act Art. 67(2)-67ter<\/td>Later of (IND filing date or patent registration date) to day before approval notice mailed<\/td>5 years<\/td>None equivalent to US\/China\/Korea<\/td>3 months from approval<\/td>Scope tied to “necessity” test (Bevacizumab); multiple approvals may separately qualify<\/td><\/tr>
China<\/td>Patent Law Art. 42(3); Implementing Regulations (eff. 20 Jan 2024)<\/td>NMPA marketing approval date minus filing date, minus 5 years (EU-style straight subtraction)<\/td>5 years<\/td>14 years from marketing approval (US-style)<\/td>3 months from approval<\/td>Limited to the new drug’s approved technical solution and indication<\/td><\/tr>
South Korea<\/td>Patent Act; KIPO administration<\/td>Domestic clinical trial period + domestic regulatory review period, minus applicant delay (Korea-only time)<\/td>5 years<\/td>14 years from approval (added in 2024-2025 revision)<\/td>3 months from approval<\/td>Limited to specific approved product and approved use only; multiple patents may qualify; all-or-nothing rule<\/td><\/tr>
Australia<\/td>Patents Act 1990 (Cth), ss. 70, 71, 77<\/td>Earliest first regulatory approval date (any qualifying substance, any party) minus patent filing date, minus 5 years<\/td>5 years<\/td>None equivalent to US\/China\/Korea<\/td>6 months from later of first approval or patent grant<\/td>Tied to earliest ARTG approval of the claimed substance class, not necessarily the patentee’s own product<\/td><\/tr>
Canada<\/td>CETA implementation, 2017 Patent Act amendments<\/td>Regulatory review delay by Health Canada, subject to a hard 2-year ceiling<\/td>2 years<\/td>Not applicable (ceiling is the extension itself)<\/td>120 days from marketing authorization<\/td>Certificate of Supplementary Protection is a distinct right, narrower duration than SPC\/PTE counterparts<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

What the Data Shows: A Peer-Reviewed Look at How Much the Math Actually Diverges<\/strong><\/h2>\n\n\n\n

The 1.55-Year Gap: What the China-EU-US Cohort Study Found<\/strong><\/h3>\n\n\n\n

A 2026 comparative study published in a peer-reviewed pharmaceutical policy journal examined new drug patent protection across China, Europe, and the United States using a Drug Development Time Period (DDTP) index and a Final Drug Patent Protection Term (FDPPT) metric, calculated from predefined equations applied to the same underlying drug set [23]<\/a>. The study reported average extension lengths of 3.56 years for China’s patent term compensation, 4.11 years for the EU’s SPC, and 2.82 years for the US’s PTE. The average DDTP \u2014 the measured time from patent filing to approval \u2014 came out to 9.79 years in Europe, 12.36 years in China, and 10.05 years in the United States. The resulting average Final Drug Patent Protection Term reached 14.32 years in Europe, 13.19 years in the United States, and 11.20 years in China.<\/p>\n\n\n\n

\n

For the same set of drugs studied, researchers found that the average European SPC term ran approximately 1.55 years longer than the average US PTE term, despite both mechanisms nominally capping at five years [23]<\/a>.<\/p>\n<\/blockquote>\n\n\n\n

The gap is directly attributable to the formula difference described above: the US’s half-testing-phase discount systematically shrinks the calculated extension relative to the EU’s straight subtraction, even when the two jurisdictions’ underlying regulatory timelines for the same drug are broadly similar. A company relying on its EU SPC duration as a proxy for its expected US PTE duration will, on this evidence, consistently overestimate the US number by more than a year on average.<\/p>\n\n\n\n

Five Types of Extension Math: An Original Taxonomy<\/strong><\/h2>\n\n\n\n

The seven systems compared in this article sort into five distinct calculation architectures, an original classification based on the mechanics described above rather than any official grouping used by a patent office or regulator:<\/p>\n\n\n\n

1. Discounted-period systems.<\/strong> The United States is the clearest example: only half of the pre-marketing testing phase counts, and only the post-patent-grant portion of both the testing phase and the review period counts at all.<\/p>\n\n\n\n

2. Straight-subtraction systems.<\/strong> The EU, UK, China, and Australia all subtract a flat five years from the full filing-to-approval (or filing-to-earliest-approval) interval, with no discount applied to any sub-period within that interval.<\/p>\n\n\n\n

3. Domestic-accrual-only systems.<\/strong> South Korea is the outlier here: the calculation counts only time actually spent in Korean clinical trials and Korean regulatory review, excluding development time that occurred anywhere else, even for the same drug and the same global regulatory dossier.<\/p>\n\n\n\n

4. Later-of-two-start-dates systems.<\/strong> Japan measures a period bounded by whichever of two triggering events (IND effectiveness or patent registration) occurred later, and by the day before approval notification, rather than performing any subtraction of a fixed number of years from a filing-to-approval span.<\/p>\n\n\n\n

5. Fixed-shallow-cap systems.<\/strong> Canada calculates the underlying regulatory delay in a manner broadly similar to the straight-subtraction group, but then imposes a categorically lower ceiling \u2014 two years rather than five \u2014 that binds far more often and far earlier than any of the other six systems’ caps.<\/p>\n\n\n\n

A Worked Scenario: Same Drug, Same Dates, Five Different Extension Lengths<\/strong><\/h2>\n\n\n\n

The following is an illustrative, hypothetical scenario constructed to demonstrate the mechanical differences described above; it does not describe a real drug, and the dates are chosen for round-number clarity rather than drawn from any actual regulatory filing. Assume a compound patent filed on 1 January 2010. Assume the IND-equivalent clinical trial application takes effect on 1 January 2013. Assume the patent is granted on 1 January 2016. Assume the marketing application is submitted on 1 January 2019. Assume marketing approval is granted, and notified, on 1 January 2023.<\/p>\n\n\n\n

US calculation (illustrative):<\/strong> The testing phase runs from 1 January 2013 to 1 January 2019, six years, of which three years (2016-2019) occurred after patent grant \u2014 so PGTP effectively reduces the countable testing phase to that post-grant portion, then halved: roughly 1.5 years. The review period runs from 2019 to 2023, four years, all after patent grant, so it counts in full. Rough illustrative PTE: 1.5 + 4 = 5.5 years, capped at the statutory 5-year maximum.<\/p>\n\n\n\n

EU calculation (illustrative):<\/strong> Filing to first EEA authorization is 1 January 2010 to 1 January 2023, thirteen years, minus five years, equals eight years \u2014 capped at the statutory 5-year maximum.<\/p>\n\n\n\n

Japan calculation (illustrative):<\/strong> The later of IND effectiveness (2013) or patent registration (2016) is 2016; the period runs from 2016 to the day before the 2023 notification, roughly seven years \u2014 capped at the statutory 5-year maximum.<\/p>\n\n\n\n

China calculation (illustrative):<\/strong> Using the EU-style formula, filing to marketing approval is thirteen years minus five, equals eight years \u2014 capped at the statutory 5-year maximum, and further bound by the 14-year total-term ceiling from approval.<\/p>\n\n\n\n

Korea calculation (illustrative):<\/strong> If only the final two years of clinical development and the regulatory review itself occurred in Korea specifically (a plausible pattern for a multinational drug that ran its pivotal trials in the US and EU first), the countable Korea-only period might be only two to three years \u2014 well under the 5-year cap, and dramatically shorter than the US, EU, Japan, or China results above for the identical underlying molecule.<\/p>\n\n\n\n

Australia calculation (illustrative):<\/strong> Assuming no third-party approval complicates the “earliest first” analysis, the calculation mirrors the EU’s: thirteen years minus five, capped at 5 years \u2014 but the Ono\/MSD precedent means this result is contingent on no competing product falling within the same claim scope at an earlier date.<\/p>\n\n\n\n

In this hypothetical, five of six jurisdictions land at or near the statutory five-year cap \u2014 but Korea, running its domestic-accrual-only formula against the same underlying drug, could plausibly land two to three years lower, simply because most of the compound’s development happened outside Korea. That divergence is invisible to any model that assumes “the extension is basically five years everywhere.”<\/p>\n\n\n\n

What This Means for Global Loss-of-Exclusivity Forecasting<\/strong><\/h2>\n\n\n\n

Why a Single “LOE Date” Column Is a Modeling Error<\/strong><\/h3>\n\n\n\n

A loss-of-exclusivity model built around one global expiration date per drug cannot represent any of the divergences documented in this article: the US’s half-testing-phase discount, the EU’s country-by-country national SPC grants that can diverge from each other even within the harmonized regulation (as the post-Seattle Genetics recalculation wave demonstrated), the UK’s growing willingness to reach different validity conclusions than EU courts on the same patent family, Japan’s later-of-two-dates formula, China’s hybrid EU-formula-with-US-cap structure, Korea’s domestic-accrual-only and all-or-nothing rules, Australia’s earliest-first-approval doctrine that can be shortened by a competitor’s product, and Canada’s categorically lower two-year ceiling. A defensible multi-jurisdiction LOE model requires a separate calculation, a separate filing-deadline tracker, and a separate case-law-monitoring process for each jurisdiction in which a company intends to rely on extended exclusivity, cross-referenced against a current patent and regulatory database such as DrugPatentWatch rather than a static internal spreadsheet that will not reflect a mid-cycle ruling like Seattle Genetics or Ono\/MSD.<\/p>\n\n\n\n

What This Means for Generic and Biosimilar Entry Planning<\/strong><\/h2>\n\n\n\n

Biologics Add a Layer: Regulatory Data Exclusivity Runs on Its Own Clock<\/strong><\/h3>\n\n\n\n

Generic and biosimilar challengers face the mirror-image version of the same modeling problem. A challenger who confirms a target patent’s US PTE has run out cannot assume the corresponding EU SPC, Japanese extension, Chinese compensation term, Korean extension, Australian extension, UK SPC, or Canadian CSP have also expired, because each is calculated, filed, and litigated independently, on its own statutory deadline, often with its own separate case law determining scope and validity. For biologics specifically, patent term extension operates alongside \u2014 not instead of \u2014 regulatory data exclusivity periods, which run on entirely separate statutory clocks in each jurisdiction (for example, the EU’s 8+2+1 data and market exclusivity structure for biologics versus the US’s twelve-year BPCIA exclusivity period), meaning a biosimilar sponsor must clear both the patent-extension calendar and the data-exclusivity calendar in each target market, and the two calendars rarely align.<\/p>\n\n\n\n

Common Mistakes IP Teams Make When Assuming Cross-Border Equivalence<\/strong><\/h2>\n\n\n\n

Mistake One: Copying the EU Filing Deadline Onto a US Timeline<\/strong><\/h4>\n\n\n\n

The EU’s six-month filing window and the US’s 60-day window are not interchangeable, and neither system offers an equitable exception for a late filing calculated on the wrong deadline. Missing the US’s tighter 60-day clock because a team defaulted to the EU’s more forgiving six-month clock forfeits the extension entirely.<\/p>\n\n\n\n

Mistake Two: Assuming the Extended Right Covers Every Later-Approved Use<\/strong><\/h4>\n\n\n\n

US and EU extended rights generally cover any later-approved use of the protected active ingredient. Korea’s extended right does not; it is limited to the specific approved product and specific approved use named in the extension grant, under Article 95 of the Korean Patent Act. A company planning a line extension into a new indication cannot assume its existing Korean extension will cover it.<\/p>\n\n\n\n

Mistake Three: Treating the Five-Year Cap as Interchangeable Across Systems<\/strong><\/h4>\n\n\n\n

Six of the seven jurisdictions compared here cap at five years; Canada caps at two. A company modeling Canadian exclusivity off its EU or US cap will overstate Canadian protection by as much as three years on any drug with a long enough underlying regulatory delay to hit both ceilings.<\/p>\n\n\n\n

Mistake Four: Missing the “Earliest First Approval” Trap in Australia<\/strong><\/h4>\n\n\n\n

Under Ono and MSD v. Sandoz, a broadly drafted Australian patent claim can be shortened by a third party’s earlier-approved product falling within the same claim scope, even if that third party’s product is a competitor’s, not the patentee’s own. Narrower claim drafting, or awareness of adjacent approvals before filing an Australian extension application, can materially change the outcome.<\/p>\n\n\n\n

Methodology and Limitations<\/strong><\/h2>\n\n\n\n

The formulas, statutory citations, and case summaries in this article are drawn from primary legal sources where available \u2014 the US Code and Manual of Patent Examining Procedure, the EU’s consolidated Regulation 469\/2009 text, the Australian Patents Act 1990 as published on AustLII, and published CJEU and Australian Federal Court judgments \u2014 supplemented by law-firm secondary analysis and one peer-reviewed comparative cohort study for the quantitative China-EU-US figures. The worked scenario in this article is explicitly labeled as an illustrative hypothetical using round, non-real dates; it is not a calculation performed on any actual drug’s regulatory record and should not be treated as legal or regulatory advice for any specific filing. Real-world PTE, SPC, and equivalent calculations depend on granular facts \u2014 exact IND effectiveness dates, exact patent issuance dates, due-diligence determinations, and claim-scope analysis \u2014 that require case-specific legal review. Extension rules in every jurisdiction discussed here are also subject to ongoing legislative and judicial change, as the 2024-2025 Korean revision and the 2024 Chinese Implementing Regulations both illustrate; readers should confirm current rules before relying on any figure in this article for an active filing decision.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n